Recomienda este artículo a tus amigos:
All About Bevacizumab Krzysztof Krzemieniecki
Precio
Mex$ 663
sin IVA
Pedido desde almacén remoto
Entrega prevista 29 de sep. - 9 de oct.
Recibe notificaciones sobre nuevos lanzamientos de Krzysztof Krzemieniecki
Nuestros clientes opinan:
Añadir a tu lista de deseos de iMusic
All About Bevacizumab
Krzysztof Krzemieniecki
Remission during sunitinib (a multikinase inhibitor and antiangiogenic drug) treatment correlates with appearance of macrocytosis. There are some suggestions that bevacizumab, an antiangiogenic drug, may result in macrocytosis as well. No available published data on the influence of bevacizumab on macrocytosis has been so far. This paper attempts to answer the question: does bevacizumab induce macrocytosis being a predictor of the response? Moreover, treatment of solid tumors and non-cancerous diseases is discussed in the second part of this paper.
| Medios de comunicación | Libros Paperback Book (Libro con tapa blanda y lomo encolado) |
| Publicado | 27 de noviembre de 2013 |
| ISBN13 | 9783659494116 |
| Editores | LAP LAMBERT Academic Publishing |
| Páginas | 72 |
| Dimensiones | 150 × 4 × 226 mm · 125 g |
| Lengua | Alemán |